This content is from: Patents

Generic company IPR study reveals “surprisingly high” institution rate

A Foley & Lardner study of generic drug company IPRs against pharmaceutical patents shows an increased willingness to use the PTAB, an above-average institution rate but below-average invalidation rate

Get Free Access to read more …

To read the full article, activate your free trial.

Get Free Access
  • Unlimited articles for one week
  • No commitments; no payment details required
  • Featuring IP strategy, copyright, patents, trademark and more!

Are you a Managing IP subscriber? Simply login here.

Related